GlassScriptPhysician profile
Matthew Alan Rohrbach
NPI 1205875192
$7,315.62
in general payments reported to CMS, 2019-2025
56 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $472 · 2021: $1,498 · 2022: $1,216 · 2023: $1,004 · 2024: $1,137 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,157.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,066.66 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $642.89 | 2019-2025 | Trulance, Xifaxan |
| Novartis Pharmaceuticals Corporation | $433.38 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $337.69 | 2019-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $293.73 | 2021-2025 | Entyvio |
| Gilead Sciences, INC. | $256.50 | 2019-2024 | |
| Novo Nordisk INC | $244.73 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $220.13 | 2021-2025 | Camzyos, Eliquis |
| Amgen INC. | $217.88 | 2020-2025 | Evenity, Tezspire |
| Lilly USA, LLC | $209.92 | 2022-2025 | Jardiance, Emgality, Mounjaro |
| Esperion Therapeutics, INC. | $178.22 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $163.74 | 2019-2021 | |
| Janssen Biotech, INC. | $162.18 | 2019-2024 | Tremfya, Stelara |
| Astrazeneca Pharmaceuticals LP | $161.92 | 2022-2025 | Farxiga, Lokelma, Breztri |
| Pfizer INC. | $161.09 | 2021-2025 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $156.22 | 2022-2025 | Nuzyra, Xhance |
| Ipsen Biopharmaceuticals, INC | $154.30 | 2025 | Iqirvo |
| Celgene Corporation | $150.74 | 2022-2024 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $148.33 | 2021-2022 | |
| Allergan, INC. | $138.33 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.14 | 2020-2025 | Jardiance, Cyltezo |
| Qol Medical, LLC | $118.81 | 2023-2025 | Sucraid, Sucraid |
| Otsuka America Pharmaceutical, INC. | $114.72 | 2022-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $109.02 | 2021-2025 | |
| Vifor Pharma, INC. | $99.61 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $96.98 | 2021 | |
| Argenx US, INC. | $93.76 | 2022-2024 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $83.17 | 2022-2023 | Ultomiris |
| Ardelyx, INC. | $79.21 | 2024-2025 | Ibsrela |
| Amarin Pharma, INC. | $77.08 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $76.90 | 2020-2021 | |
| Braintree Laboratories, INC. | $69.82 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $65.88 | 2020-2022 | |
| Organon LLC | $58.87 | 2023 | Hadlima, Renflexis, Ontruzant |
| Shield Therapeutics INC | $54.47 | 2024 | |
| Merck Sharp & Dohme LLC | $43.32 | 2019-2022 | |
| Daiichi Sankyo INC. | $38.77 | 2022-2023 | Injectafer |
| Biohaven Pharmaceutical Holding Company LTD. | $38.38 | 2022 | |
| Biogen, INC. | $38.15 | 2023-2025 | Vumerity, Tysabri |
| Celltrion USA INC. | $34.50 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $30.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $29.66 | 2024 | Voquezna |
| Redhill Biopharma INC. | $27.26 | 2023-2024 | Talicia |
| Endo Pharmaceuticals INC. | $23.55 | 2020-2021 | |
| Philips North America LLC | $23.39 | 2024 | (5044) Mcot |
| Insulet Corporation | $21.46 | 2024 | Omnipod |
| Baxter Healthcare | $20.75 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Ucb, INC. | $19.99 | 2019 | |
| Ferring Pharmaceuticals INC. | $18.15 | 2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $16.25 | 2022 | |
| Corcept Therapeutics | $13.74 | 2021 | |
| Neurocrine Biosciences, INC. | $13.19 | 2022 | |
| Concordia Pharmaceuticals INC. | $12.90 | 2019 | |
| Genentech USA, INC. | $12.72 | 2020 | |
| Lundbeck LLC | $11.31 | 2020 | |
| Glaxosmithkline, LLC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Rohrbach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.